Together, these findings enhance our understanding of the molecular mechanisms underlying human lung cancer and underscore the potential of developing novel inhibitors targeting MEOX2, GLI-1, and ncBAF complex subunits, as previously proposed in lung disease studies [23], while also emphasizing the potential therapeutic value of reinducing SMARCB1 expression in human lung malignant diseases. Here, MEOX2 is linked to lung carcinoma.